Graphite Bio is harnessing the unprecedented power of high efficiency, targeted gene integration to cure serious diseases.
Co-founded by pioneers in genetic medicine and led by a seasoned management team, Graphite Bio is a next-generation gene editing company focused on the development of best-in-disease therapies for patients suffering from serious genetic disorders and beyond. Our highly differentiated gene integration platform harnesses the power of CRISPR and natural DNA repair processes to achieve targeted gene integration to precisely repair genetic defects at their source.
Our approach is designed to overcome past limitations of gene editing, with the potential to rewrite genetic therapies with precision and efficiency.
Our name is rooted in DNA discovery and embodies our singular purpose of fulfilling the unlimited potential of gene replacement therapy to improve human health.
At Graphite Bio, bold ideas, bright minds and a collaborative culture are brought together with the aim of changing patients’ lives.
Graphite Bio operates at the cutting edge of the gene editing field, advancing high efficiency, targeted gene integration to precisely deliver therapies that treat and potentially cure serious diseases.
Latest News
Press Release | May 16, 2022
Press Release | May 12, 2022
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
